Pharmacological inhibition of KDM1A/LSD1 enhances estrogen receptor beta-mediated tumor suppression in ovarian cancer
Prabhakar Pitta Venkata(The University of Texas Health Science Center at San Antonio), Gangadhara R. Sareddy(The University of Texas Health Science Center at San Antonio)
Cited by 18
Related Papers
Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma
|Scientific Reports|2016|71
KDM1A inhibition augments the efficacy of rapamycin for the treatment of endometrial cancer
|Cancer Letters|2021|19